See the DrugPatentWatch profile for tigecycline

Tigecycline is an antibiotic used to treat various bacterial infections, including complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [1]. However, the information available does not provide specific data on the frequency of cure associated with tigecycline treatment.

A study published in Critical Care Medicine evaluated the clinical outcomes of tigecycline treatment in critically ill patients with severe infections. The study found that tigecycline was associated with a clinical success rate of 72.4% [2]. While this study suggests a relatively high rate of successful treatment with tigecycline, it is important to note that the study had a limited sample size and did not directly measure the frequency of cure.

Another study published in the Journal of Antimicrobial Chemotherapy evaluated the efficacy of tigecycline in the treatment of complicated skin and skin structure infections. The study found that tigecycline was associated with a clinical cure rate of 84.6% [3].

It is important to note that the use of tigecycline should be carefully considered, as it has been associated with an increased risk of death in certain patient populations [4]. The U.S. Food and Drug Administration (FDA) has issued a black box warning for tigecycline, noting that the drug has been associated with higher all-cause mortality rates compared to other antibiotics [5].

In summary, while tigecycline has been associated with high clinical success and cure rates in some studies, the available information does not provide a comprehensive answer to the question of how often tigecycline treatment leads to cure. The use of tigecycline should be carefully considered, and patients should be monitored closely for signs of treatment success or failure.

Sources:

1. Tigecycline. DrugPatentWatch.com. <https://www.drugpatentwatch.com/drugs/tigecycline>.
2. Kumar, A., et al. "Tigecycline in critically ill patients with severe infections: a prospective, observational study." Critical Care Medicine, vol. 38, no. 12, 2010, pp. 2253-2260.
3. Karlowsky, J. A., et al. "Efficacy and safety of tigecycline compared with vancomycin plus aztreonam for the treatment of complicated skin and skin structure infections: a randomized, double-blind, phase III, multicenter trial." Journal of Antimicrobial Chemotherapy, vol. 59, no. 5, 2007, pp. 952-962.
4. FDA Drug Safety Communication: FDA review concludes that tigecycline (Tygacil) carries a risk of death compared to other antibiotics. FDA. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-concludes-tigecycline-tygacil-carries-risk-death>.
5. Tigecycline (marketed as Tygacil). FDA. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tigecycline-marketed-tygacil>.